HEXIM2 antisense RNA 2 (HEXIM2-AS2)

HEXIM2 antisense RNA 2 (HEXIM2-AS2) is a long non-coding RNA (lncRNA) identified as an oncogenic lncRNA strongly associated with hepatocellular carcinoma (HCC)[3][6][7]. It is also referenced as HCC-specific super-enhancer-associated oncogenic lncRNA 3 and by other aliases, such as HSAL3 and RP13-890H12.2[3][8]. Its inclusion in resources focused on cancer genomics establishes its functional role as a non-coding regulator rather than a classical receptor, enzyme, or transporter. HEXIM2-AS2 acts by regulating gene expression through interactions with DNA, proteins, and other RNAs, which can promote oncogenic processes such as cellular proliferation and tumor progression typically seen in HCC[2][7]. Its expression is cancer-associated, particularly in liver cancer, and its biology implicates it as a potential diagnostic or prognostic biomarker and a therapeutic target for HCC, though specific pharmacological strategies and associated safety issues are still under investigation[7].

Other names

HSAL3RP13-890H12.2HCC-specific SE-associated oncogenic lncRNA 3